Cargando…
Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors
Overexpression of CD47 is frequently observed in various types of human malignancies, inhibiting myeloid-mediated elimination of tumor cells and affecting the prognosis of cancer patients. By mapping biomarker expression, immuno-positron emission tomography has been increasingly used for patient scr...
Autores principales: | Zhang, You, Zhang, Di, An, Shuxian, Liu, Qiufang, Liang, Chenyi, Li, Juan, Liu, Ping, Wu, Changfeng, Huang, Gang, Wei, Weijun, Liu, Jianjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AAAS
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017100/ https://www.ncbi.nlm.nih.gov/pubmed/36939440 http://dx.doi.org/10.34133/research.0077 |
Ejemplares similares
-
Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019) -
Development and comparison of (68)Ga/(18)F/(64)Cu-labeled nanobody tracers probing Claudin18.2
por: Wei, Weijun, et al.
Publicado: (2022) -
Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer
por: D’Huyvetter, Matthias, et al.
Publicado: (2014) -
Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
por: Ma, Linlin, et al.
Publicado: (2020) -
ImmunoPET imaging of human CD8(+) T cells with novel (68)Ga-labeled nanobody companion diagnostic agents
por: Zhao, Haitao, et al.
Publicado: (2021)